These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 15472905)
1. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Almholt K; Lund LR; Rygaard J; Nielsen BS; Danø K; Rømer J; Johnsen M Int J Cancer; 2005 Feb; 113(4):525-32. PubMed ID: 15472905 [TBL] [Abstract][Full Text] [Related]
2. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975 [TBL] [Abstract][Full Text] [Related]
3. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700 [TBL] [Abstract][Full Text] [Related]
5. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR. Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548 [TBL] [Abstract][Full Text] [Related]
6. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Vasiljeva O; Papazoglou A; Krüger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T Cancer Res; 2006 May; 66(10):5242-50. PubMed ID: 16707449 [TBL] [Abstract][Full Text] [Related]
7. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model. Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246 [TBL] [Abstract][Full Text] [Related]
8. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Almholt K; Juncker-Jensen A; Laerum OD; Danø K; Johnsen M; Lund LR; Rømer J Mol Cancer Ther; 2008 Sep; 7(9):2758-67. PubMed ID: 18790756 [TBL] [Abstract][Full Text] [Related]
9. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Cuevas BD; Winter-Vann AM; Johnson NL; Johnson GL Oncogene; 2006 Aug; 25(36):4998-5010. PubMed ID: 16568086 [TBL] [Abstract][Full Text] [Related]
10. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932 [TBL] [Abstract][Full Text] [Related]
11. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639 [TBL] [Abstract][Full Text] [Related]
12. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice. Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086 [TBL] [Abstract][Full Text] [Related]
13. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Mitra SK; Lim ST; Chi A; Schlaepfer DD Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501 [TBL] [Abstract][Full Text] [Related]
15. Increased bone formation in mice lacking plasminogen activators. Daci E; Everts V; Torrekens S; Van Herck E; Tigchelaar-Gutterr W; Bouillon R; Carmeliet G J Bone Miner Res; 2003 Jul; 18(7):1167-76. PubMed ID: 12854826 [TBL] [Abstract][Full Text] [Related]
16. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650 [TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Sevenich L; Werner F; Gajda M; Schurigt U; Sieber C; Müller S; Follo M; Peters C; Reinheckel T Oncogene; 2011 Jan; 30(1):54-64. PubMed ID: 20818432 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966 [TBL] [Abstract][Full Text] [Related]
19. Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation. Hägglund AC; Ny A; Liu K; Ny T Endocrinology; 1996 Dec; 137(12):5671-7. PubMed ID: 8940398 [TBL] [Abstract][Full Text] [Related]
20. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors. Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]